2578results about "Amide active ingredients" patented technology

Computer-implemented methods of predicting the QTc of a subject in response to administration of QTc prolonging drugs, especially those that are dose adjusted for renal function, such as antiarrhythmic drugs. Included is a method of administering an antiarrhythmic drug to a subject, comprising: providing as inputs into a treatment management application i) Baseline QTc and ii) at least a Creatinine Clearance, Weight, Age, Sex, or Heart Rate; the treatment management application providing as an output one or more predicted QTc or predicted QTc range for the subject expected from administration of a 1-5 hour IV dose, alone or followed by one or more oral doses, of an antiarrhythmic drug to the subject; and upon the one or more QTc or QTc range being within an acceptable range, administering the 1-5 hour IV dose to the subject optionally followed by administering one or more of the oral doses to the subject.

The present disclosure provides methods of treating opioid use disorder in a patient in need thereof by intravenously administering to the patient a therapeutically effective amount of ibogaine or pharmaceutically acceptable salt thereof.

Methods of administering sotalol hydrochloride in an amount effective for treating one or more cardiovascular disease or disorder in pediatric patients are described and include IV and / or oral doses based on age-specific creatinine clearance ranges.

The invention relates to the technical field of pharmaceutical preparations, and discloses a composition with liver protection and antioxidation effects and a preparation method thereof.The composition is prepared from galactosamine modified astragalus membranaceus exosome, schisandra chinensis nanocrystals, liquorice-chitosan nanoparticles, lactobacillus acidophilus freeze-dried powder, beta-(1, 3) / (1, 3, 4-tetramethyl-1, 3-pentanediol monoisobutyrate) sourced from saccharomyces cerevisiae, and beta-(1, 3, 4-tetramethyl-1, 3-pentanediol monoisobutyrate). And (6) a dextran, grape exosome-curcumin hybrid vesicle freeze-dried powder, a curcumin-mitochondrial targeting peptide compound, a resveratrol-hydroxypropyl-beta-cyclodextrin inclusion compound and reduced panthenol. According to the liver-protecting and anti-oxidation composition disclosed by the invention, multi-dimensional intervention on liver protection is realized through an elaborately designed ternary system. The system is composed of a traditional Chinese medicine extract, a microorganism-plant exosome combination and a high-bioavailability antioxidant, all the parts have a synergistic effect, and the liver protection effect is remarkably improved.

The present invention provides novel methods of administering sotalol hydrochloride to patients in need thereof.

The present invention provides novel methods of initiating and escalating sotalol hydrochloride in patients in need thereof.

Disclosed are methods of treating a subject having clinically significant signs and symptoms associated with blood cell differentiation and treated with an agent that reduces the level and / or activity of BRG1 and / or BRM. The methods disclosed herein may include, e.g., administering to the subject an effective amount of a corticosteroid, hydroxyurea, or furosemide, or subjecting the subject to leukapheresis.

The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and / or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.

The invention provides combination therapies comprising disease modifying anti-rheumatic drugs and mitochondrial complex I modulator (MCIM) compounds, which find utility in the medical field of inflammatory and progressive disorders, for example autoimmune diseases such as arthritis.

The present invention relates to N-palmitoyl ethanolamide for the treatment of inflammatory pain in combination with a non-steroidal anti-inflammatory drug, to the use of N-palmitoyl ethanolamide (referred to as palmitoyl ethanolamide or PEA) in combination with a non-steroidal anti-inflammatory drug for the treatment of inflammatory pain. Specifically, the present invention relates to palmitoyl ethanolamide for use in the treatment of inflammatory pain, in particular non-neurological inflammatory pain, in which palmitoyl ethanolamide is administered in combination or in combination with a non-steroidal anti-inflammatory drug as needed, in which the administration is separate, combined or simultaneous.

The invention discloses an antibacterial peptide simulant based on adamantane modification and application of the antibacterial peptide simulant. The preparation method comprises the following steps: performing amide condensation on Fmoc amino acid to obtain a compound of which the carboxyl terminal is modified by amantadine or Boc protected aliphatic amine, and then removing an Fmoc group by piperidine to obtain a series of amantadine modified crude products and Boc protected aliphatic amine modified intermediate compounds; the intermediate compound is subjected to amide condensation to obtain a compound of which the amino terminal is further modified by adamantanic acid, then other protecting groups are cracked by trifluoroacetic acid to obtain a series of adamantanic acid modified crude products, and the crude products are purified to obtain the adamantane modified peptidomimetic. The adamantane modified peptidomimetic is used for preparing drugs for treating infectious diseases caused by sensitive bacteria and drug-resistant bacteria, has efficient antibacterial activity and low toxicity, and is not influenced by a traditional drug-resistant mechanism.

The present invention relates to the use of N-palmitoylethanolamide (known as palmitoylethanolamide or PEA) in combination with a non-steroidal anti-inflammatory drug in the treatment of inflammatory pain. In particular, the present invention is directed to palmitoylethanolamide for use in the treatment of inflammatory pain, in particular non-neuropathic inflammatory pain, where palmitoylethanolamide is administered as needed in association or combination with a non-steroidal anti-inflammatory drug, where said administration is separate, combined, or simultaneous.

The invention belongs to the technical field of stem cell biological preparations, and particularly relates to an anti-aging compound preparation based on stem cells and application of the anti-aging compound preparation in delaying skin aging. The composition is composed of an inner water phase, a middle oil phase and an outer water phase, wherein the inner water phase is prepared from the following components: stem cell exosomes, hyaluronic acid, nicotinamide ribose, trehalose, mannitol, glycine and a citric acid buffer solution; the medium oil phase is prepared from the following components: medium chain triglyceride, shea butter, vitamin E succinate, PEG (Polyethylene Glycol) modified ceramide NP and cholesterol succinic acid monoester; the external water phase is prepared from the following components: polydatin, cellulose nanocrystals and an emulsifying agent. On the basis of a W / O / W emulsion system, a multi-layer anti-aging mechanism is constructed by utilizing a three-dimensional delivery framework of an inner water phase, an oil phase and an outer water phase and space-time synergy of active ingredients, the exosome permeation efficiency is improved through microneedle introduction, and the anti-oxidation and barrier repair effects are achieved by using multiple ingredients.

The invention belongs to the technical field of biological medicines, and particularly relates to an iron-based nano material, a preparation method and application of the iron-based nano material in preparation of medicines for treating breast cancer. The iron-based nano material is formed by loading a ferroptosis inducer on a nano carrier; the nano carrier is an iron-based metal organic framework material Fe-MOF (Metal Organic Framework). A product FEH for treating breast cancer is obtained based on coupling of the iron-based nano-material provided by the invention with a targeted drug such as trastuzumab. The FEH provides a new method for developing a nano platform with an antibody function, and realizes a treatment strategy of trastuzumab and ferroptosis combined anti-tumor. As a safe and effective tumor treatment strategy, the EFH has huge clinical transformation potential.

The invention discloses application of an IL-8 inhibitor to treatment of diabetic retinopathy patients. The molecular mechanism of IL-8 in the diabetic retinopathy generation and development process is deeply explored, a theoretical basis is provided for SB225002 to influence the generation and development of diabetic retinopathy through inflammation, and a feasible direction is provided for diabetic retinopathy treatment and targeted retinal neovascularization treatment drugs.

The present disclosure is related to a conjugate of an active drug and a glycosaminoglycan, such as hyaluronic acid (HA). For example, the active drug can be lenalidomide, nimesulide, or gemcitabine. The conjugate of the present disclosure is useful in the treatment of certain cancers.

The invention relates to a dihydroarteannuic acid compound as well as a preparation method and application thereof. The structure of the dihydroarteannuic acid compound is shown as a formula I in the specification. The dihydroarteannuic acid compound or the pharmaceutically or cosmetically acceptable salt of the dihydroarteannuic acid compound shows good melanogenesis inhibition activity and anti-inflammatory activity at the cellular level, has good safety, can be used as a melanogenesis inhibitor, and can be used for preparing anti-inflammatory drugs. The composition is used for preparing medicines for treating senile plaques, chloasma, freckles and hyperpigmentation after inflammation and cosmetics for whitening and removing freckles.

The present invention relates to a use of THBS1 as a novel combination drug target that can overcome drug resistance of a targeted anticancer agent. A THBS1 inhibitor according to the present invention inhibits the drug resistance of a target anticancer agent and thus increases an anticancer effect when administered in combination with a target anticancer agent. Accordingly, the present invention can overcome resistance to a targeted anticancer agent and increase a treatment success rate of anticancer drugs for cancer patients, thereby suggesting new possibilities for treatment strategies using targeted anticancer drugs and contributing to the realization of precision medicine.

Provided herein are pharmaceutical compositions, each comprising a phenylsulfonamide, for example, a compound of Formula I, or an enantiomer, a mixture of enantiomers, a mixture of tow ore more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and a pharmaceutically acceptable excipient. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurodegenerative disease.

The invention provides a marine biological alkali compound. The chemical formula of the marine biological alkali compound is as follows: # imgabs0. The marine biological alkali compound or pharmaceutically acceptable salt thereof can be used for preparing antibacterial drugs or anti-infective drugs. The invention also provides a separation and extraction preparation method or a chemical synthesis preparation method of the marine alkaloid compound or the pharmaceutically acceptable salt thereof, and the preparation method is simple and easy to industrialize. The invention also provides application of the marine biological alkali compound or the pharmaceutically acceptable salt thereof in preparation of antibacterial drugs or anti-infection drugs for human or fish.

Provided herein are novel compounds (e.g., Formula I), pharmaceutical compositions, and methods of use for treating a variety of diseases or disorders, such as cancer. (I)

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a preparation method and application of N-(3-chloro-4-fluorophenyl)-4-fluoro-3, 5-dimethyl benzenesulfonamide and analogues thereof, and a medicinal composition of the N-(3-chloro-4-fluorophenyl)-4-fluoro-3, 5-dimethyl benzenesulfonamide and the analogues thereof. The method comprises the following steps: dissolving a compound 1 and a compound 2 in an organic solvent, adding an acid-binding agent, carrying out a stirring reaction at 20-100 DEG C, and carrying out TLC detection until raw material fluorescence disappears so as to complete the reaction; and carrying out spin-drying on the reaction liquid, and carrying out crystallization or column chromatography separation on a crude product to obtain N-(3-chloro-4-fluorophenyl)-4-fluoro-3, 5-dimethyl benzenesulfonamide and the analogue of N-(3-chloro-4-fluorophenyl)-4-fluoro-3, 5-dimethyl benzenesulfonamide. N-(3-chloro-4-fluorophenyl)-4-fluoro-3, 5-dimethylbenzenesulfonamide and analogues thereof are used for recovering the physiological level of TERT in senescent tissues, and N-(3-chloro-4-fluorophenyl)-4-fluoro-3, 5-dimethylbenzenesulfonamide and analogues thereof are used for preparing oral pharmaceutical compositions. The N-(3-chloro-4-fluorophenyl)-4-fluoro-3, 5-dimethylbenzenesulfonamide and the analogue thereof can be used for recovering the physiological level of TERT (telomerase reverse transcriptase) of the whole aging tissue and relieving various aging characteristics.

A liposomal composition includes at least one phospholipid, at least one biosurfactant, water, and optionally at least one solvent. The at least one solvent is an alcohol with at least three carbon atoms or a polyol. A process encapsulates at least one cosmetic, pharmaceutical and / or nutraceutical active ingredient. A formulation and a capsule include said liposomnal composition.

The invention relates to a cystamine derivative and application thereof in preparation of a medicine with an anti-inflammatory effect. According to the application of the cystamine derivative or the salt of the cystamine derivative in preparation of the medicine with the anti-inflammatory effect, the cystamine derivative has the structural characteristics shown in a formula (1), a formula (2) or a formula (3). The research finds that the cystamine derivative or the salt thereof with the structural general formula can play a better anti-inflammatory effect, can be used for preventing and treating or improving inflammatory diseases, and has the characteristics of low liver and kidney toxicity, high efficiency and safety. # imgabs0 #

Provided herein are compositions and methods for treating patients with Usher syndrome associated retinitis pigmentosa (UARP) comprising identifying that the subject has UARP and administering to the animal or human an effective amount of an N-acetylcysteine amide (NACA) sufficient to protect vision and inhibit degradation of Ellipsoid Zone (EZ) area and retinal sensitivity. In one example, the NACA formulation is doses at 50, 100, 200, 201, 210, 225, 250, 275, 300, 350, 400, 450, 500, 600, 700, 750, 800, 900, or 1,000 mg / day.

The invention relates to an arteannuic acid compound as well as a preparation method and application thereof. The structure of the arteannuic acid compound is shown as a formula I in the specification. The arteannuic acid compound or the pharmaceutically or cosmetically acceptable salt thereof provided by the invention shows good melanogenesis inhibition activity and anti-inflammatory activity at a cellular level, has good safety, can be used as an inhibitor for melanogenesis, and can be used for preparing anti-inflammatory drugs. The composition is used for preparing medicines for treating senile plaques, chloasma, freckles and hyperpigmentation after inflammation and cosmetics for whitening and removing freckles.

The invention discloses a scar-removing microneedle body and a scar-removing microneedle composite patch, and belongs to the technical field of microneedle patches, the scar-removing microneedle composite patch comprises a patch layer and a microneedle layer, the patch layer comprises a silica gel layer and a substrate layer, and the substrate layer is arranged between the microneedle layer and the silica gel layer; the microneedle layer comprises a plurality of microneedle bodies, each microneedle body comprises an epidermal segment and a dermis segment, and the epidermal segment is composed of a matrix and a first scar removing component; the dermis segment is composed of a matrix and a second scar removing component; the scar-removing microneedle body is of a two-section structural design, two scar-removing components are combined, different scar-removing components of epidermal layer targeting and corium layer targeting are accurately provided to a target skin layer, individual scar-removing components can be concentrated on the target skin layer, and the scar-removing effect is improved. Meanwhile, side effects or interference possibly generated by scar removing components on different skin layers can be avoided, and the precise and efficient compound scar removing effect is achieved.

To provide a composition and a pharmaceutical composition each of which exhibits, while suppressing rapid degeneration of tissues caused by administration thereof, excellent regulatory activity for chemokine receptors and excellent medicinal effects on a posterior eye disease and the like.SOLUTION: Provided are a composition comprising a GAG derivative and a chemokine receptor activity regulator, and a pharmaceutical composition comprising the composition.SELECTED DRAWING: None